巻号一覧
23 巻 (1992)
- 4 号 p. 635-
- 3 号 p. 557-
- 2 号 p. 439-
- 1 号 p. 11-
23 巻, 3 号
選択された号の論文の9件中1～9を表示しています
- |<
- <
- 1
- >
- >|
-
用量検討のための多施設二重盲検比較試験新谷 博一, 加藤 和三, 杉本 恒明, 新 博次, 比江嶋 一昌, 飯沼 宏之, 片桐 敬, 笠貫 宏, 井上 博, 佐久間 昭1992 年 23 巻 3 号 p. 557-572
発行日: 1992/09/30
公開日: 2010/04/30
ジャーナル フリーA multicenter double-blind controlled study was conducted in 109 patients with supraventricular premature contractions (SVPC) to find an optimal dose regimen for pilsicainide hydrochloride, a new antiarrhythmic agent.
Patients were administered any one of daily oral doses of 75mg (low), 150mg (intermediate) and 225mg (high) of pilsicainide hydrochloride divided into three times a day for two weeks after one to two weeks of control period.
Improvement of arrhythmia was assessed by the reduction in frequency and the grade of premature contractions, and global improvement was assessed from the results of improvement of arrhythmia and subjective symptoms. In the improvement of arrhythmia as well as global improvement, the high and intermediate dose groups showed significantly higher response rate than that in the low dose group, whereas no significant difference was observed between the intermediate and high dose groups.
There were no significant differences in the overall safety rating among the three dose levels. Incidence of the cases in which some problems concerning safety was pointed out in the low, intermediate and high dose groups, were 6%, 11% and 21% respectively, and no serious case was observed.
The clinical usefulness of the drug was assessed, based on the results of global improvement and the overall safety. The drug was assessed to be useful or better in 29% of the patients of low dose group, 61% of intermediate dose group, 70% of high dose group. The intermediate dose group showed significantly higher usefulness rating than that in the low dose group, but no significant difference was observed between the high and intermediate dose group.
In conclusion, pilsicainide hydrochloride was shown to be useful in the supraventricular premature contractions, and an optimal dose of 150mg/day was suggested.抄録全体を表示PDF形式でダウンロード (1585K) -
小林 真一, 内田 英二, 小口 勝司, 安原 一, 越川 昭三, 秋沢 忠男, 高山 公洋, 永井 哲士, 尾熊 隆嘉, 島村 健治, 河 ...1992 年 23 巻 3 号 p. 573-580
発行日: 1992/09/30
公開日: 2010/04/30
ジャーナル フリーRilmazafone Hydrochloriode (RZ), a prodrug of benzodiazepine derivatives, is used clinically as a sleep inducer.
The pharmacokinetics of RZ in patients were studied to determine the clinical dose for patients with chronic renal failure.
Five patients (2 male, 3 female, aged 44-62yr) who participated in this study were undergoing hemodialysis. They were given RZ (1mg, p. o.) one time on the day of dialysis, and 5-7 days later on the day of non-dialysis. Blood samples were collected for 48hr after each administration to determine the concentrations of metabolites of RZ (M1, M2, MA, M3, M4). Pharmacokinetic profiles of RZ in these patients were compared with those in healthy volunteers (2mg, p. o.). Despite the dose difference and body weight difference (patients, 53kg (mean), volunteers, 60kg), Cmax's of M1 and M4 in patients were double and AUC's were five times those in healthy volunteers. T1/2's of M1, M2, M4 in patients were two to four times longer than those in healthy volunteers. The pharmacokinetic profiles of total active metabolites in patients were not significantly different. However, plasma concentration-time curves of potent active metabolites (M1, M2) in patients would probably be higher than those in healthy volunteers, if both were given the same dose of RZ.
These results may indicate that dosage of RZ in patients with chronic renal failure should be started from 1mg, because of the reduction of hepatic metabolism and renal excretion of RZ in these patients.抄録全体を表示PDF形式でダウンロード (684K) -
有田 幹雄, 豊田 康誠, 中村 千種, 秋津 寿男, 中村 吉成, 吉川 博之, 上野 雄二, 西尾 一郎, 増山 善明1992 年 23 巻 3 号 p. 581-586
発行日: 1992/09/30
公開日: 2010/04/30
ジャーナル フリーThe effects of amlodipine, a Ca2+-channel blockade, on hemodynamic and hormonal responses to exercise were evaluated in patients with essential hypertension. In 7 patients (WHO stage, I, II), the exercise by bicycle ergometer was done before and after amlodipine treatment (5mg/day, 2-4wk). The hemodynamic responses to exercise were evaluated by changes in systolic and diastolic blood pressure, heart rate, cardiac output measured by UCG, and total peripheral resistance. In addition, plasma norepinephrine concentration (PNE) and renin activity (PRA) were measured at rest and peak exercise. A significant rise in systolic and diastolic blood pressure associated with tachycardia was observed during exercise. An increase in cardiac output was also observed, but the total peripheral resistance decreased by exercise. The PNE and PRA were increased by exercise. Amlodipine reduced both basal blood pressure and exercise-induced rise in blood pressure. On the other hand, the basal heart rate and exercise-induced increase in heart rate were not affected by amlodipine treatment. These changes were similar to those in pretreatment of amlodipine. Amlodipine did not produce any significant changes in PNE both at rest and during exercise. Although the PRA at rest was increased by amlodipine treatment, the increase in PRA induced by exercise was unaffected by amlodipine. These findings indicate that amlodipine might have some different effects on hemodynamics and hormones compared with the other Ca2+-channel blockades which produce an enhanced response of hemodynamics and hormonal system to exercise.抄録全体を表示PDF形式でダウンロード (638K) -
メキシレチンとの交差法による比較検討小沢 俊, 中村 仁, 高松 俊彰, 宇田 毅彦, 鳩貝 文彦, 永井 敏雄, 中村 眞人, 松岡 祐之, 片岡 満男, 稲垣 正司, 飯島 ...1992 年 23 巻 3 号 p. 587-597
発行日: 1992/09/30
公開日: 2010/04/30
ジャーナル フリーPurpose: A comparison study was Preformed for the clinical effects of aprindine (AP) on ventricular extrasystole in the same patient, using mexiletine (MX) as a control, by a cross-over method that used the envelope method.
Method: Twenty-two patients from nine facilities with ventricular extrasystole of 5, 000/day or more were administered AP 40mg/day and MX 300mg/day.
Prior to treatment and at the completion of each treatment, recordings of DCG, electrocardiogram at rest, and measurements of blood concentration were carried out.
Results: A reduction rate of 50% or more in the total number of extrasystoles was observed in 12 patients (54%) administered AP, in 11 administered MX (50%), and although a Lown classification of IV or higher was observed in 16 patients, it improved to III or less in eight AP patients and in seven MX patients. In an analysis by the Lerenz plot method, the coupling interval was prolonged significantly by the administration of AP. The PQ interval and QRS width also were prolonged significantly by the administration of AP.
Conclusion: AP was considered to be a drug that strongly suppresses conducting systems of the heart, especially atrial and intraventricular conduction.抄録全体を表示PDF形式でダウンロード (1293K) -
Haruichi KOHNO, Hiroaki KUBO, Kouichi FURUKAWA, Atsushi TAKADA1992 年 23 巻 3 号 p. 599-603
発行日: 1992/09/30
公開日: 2010/04/30
ジャーナル フリー1. Determination of isoniazid acetylation phenotype was carried out in 213 Japanese patients with pulmonary tuberculosis (control group) and 52 Japanese patients with both non-insulin-dependent diabetes mellitus and pulmonary tuberculosis (NIDDM group). 2. Distribution of the log (INH/AcINH) ratio of the Japanese population was observed in the two groups. 3. Assuming an antimode of 0.6, the proportion of slow acetylators was found to be 10.0% in Japanese pulmonary tuberculosis patients, and 3.6% in Japanese NIDDM patients with pulmonary tuberculosis. These differences were not significant statistically.抄録全体を表示PDF形式でダウンロード (532K) -
古野 勝志, 五味田 裕, 荒木 泰典, 真庭 聡, 大塚 頌子, 大田原 俊輔1992 年 23 巻 3 号 p. 605-608
発行日: 1992/09/30
公開日: 2010/04/30
ジャーナル フリーBromide (Br) serum concentrations were determined by the spectrophotometric assay in patients with epilepsy to whom Br and other antiepileptic drugs were administered. Serum samples or standard solutions (0-2, 000μg/ml) were pretreated by adding perchloric acid, and were centrifuged. Twenty μl of the supernatant was transferred to the 10ml test tube, and 0.2mol/l acetate buffer (pH5.5) and 0.625mmol/l sodium fluorescein were added to it. After 200μl of 8mmol/l chloramine-T solution was added and was incubated for 10min, the reaction was stopped by adding sodium thiosulfate and sodium carbonate solution. The absorbance was determined at 520nm by spectrophotometer. Coefficients of variations (CVs) were 1.7 to 2.2% in within-day assay (n=10) and 3.5 to 4.9% in between-day assay (10 days). The recovery rate of Br ranged from 91.5 to 109.9% (mean 102.7%). This method was not interfered by other various anti-epileptic drugs. We observed that epileptic attacks were clearly suppressed by KBr administration in a patient with intractable epilepsy who had not been controlled by high doses of valproate-Na and phenobarbital therapy. In this patient, Br serum concentration for suppressing the epileptic attacks was from 1, 560 to 1, 640μg/ml. The present method for determining Br serum concentration was so simple, rapid and accurate, i. e., being useful for monitoring the Br serum concentration in the therapy of epilepsy.抄録全体を表示PDF形式でダウンロード (421K) -
1992 年 23 巻 3 号 p. 609-621
発行日: 1992/09/30
公開日: 2010/04/30
ジャーナル フリーPDF形式でダウンロード (1909K) -
1992 年 23 巻 3 号 p. E63a-E64
発行日: 1992年
公開日: 2010/04/30
ジャーナル フリーPDF形式でダウンロード (2637K) -
1992 年 23 巻 3 号 p. E63b-E64
発行日: 1992年
公開日: 2010/04/30
ジャーナル フリーPDF形式でダウンロード (2637K)
- |<
- <
- 1
- >
- >|